US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Merck & Co (NY:MRK)

141.94 +2.40 (+1.72%)
Official Closing Price Updated: 7:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stay informed with the top movers within the dow jones index on Tuesday. ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
Monday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
Which S&P500 stocks are moving on Monday? ↗
Via Chartmill
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note ↗
With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%. 
Via MarketBeat
Topics Bonds Retirement
News headline image
3 of the Best ETFs to Buy and Hold if a Recession Is Coming ↗
VHT, BND, and VOO could be your best bets in the next economic downturn. 
Via The Motley Fool
Topics ETFs Economy Regulatory Compliance
What's going on in today's session: dow jones movers ↗
Via Chartmill
News headline image
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
From Merck & Co., Inc
Via Business Wire
Stay informed with the top movers within the dow jones index on Wednesday. ↗
Via Chartmill
News headline image
Prediction: Moderna Stock Will Soar 100% by 2030 ↗
The company could enter a fresh growth phase. 
Via The Motley Fool
News headline image
2 Outstanding Dividend Stocks to Buy and Hold for a Decade ↗
There is probably no dividend cut on the horizon for these healthcare companies. 
Via The Motley Fool
Topics Artificial Intelligence
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
3 Healthcare Dividend Stocks Offering More Than Just Income ↗
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027. 
Via MarketBeat
News headline image
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
From Merck & Co., Inc.
Via Business Wire
News headline image
SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. ↗
SHCD is missing some of the healthiest dividend stocks. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
3 Cash-Producing Stocks with Open Questions
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
Which dow jones stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers. L... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
From Merck & Co., Inc.
Via Business Wire
Friday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
News headline image
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
From Merck & Co., Inc.
Via Business Wire
Stay informed with the top movers within the dow jones index on Thursday. ↗
Via Chartmill
Thursday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
News headline image
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
From Merck & Co.
Via Business Wire
Wednesday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
Stay informed with the top movers within the dow jones index on Wednesday. ↗
Via Chartmill
News headline image
3 Healthcare Stocks with Warning Signs
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >